MENU
HRTS
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for HRTS with price predictions
Nov 11, 2026

Momentum Indicator for HRTS turns positive, indicating new upward trend

HRTS saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator turned positive. In 44 of the 48 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HRTS just turned positive on October 09, 2026. Looking at past instances where HRTS's MACD turned positive, the stock continued to rise in 33 of 35 cases over the following month. The odds of a continued upward trend are 90%.

HRTS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HRTS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in 158 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 112 of 126 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Bearish Trend Analysis

The 10-day RSI Indicator for HRTS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 13 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

HRTS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF (HRTS) ETF is 127.33B. The market cap for tickers in the group ranges from 1.71B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is STOK at 1.71B.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF (HRTS) ETF was -1%. For the same ETF, the average monthly price growth was 8%, and the average quarterly price growth was 18%. KOD experienced the highest price growth at 11%, while ARWR experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF (HRTS) ETF was -46%. For the same stocks of the ETF, the average monthly volume growth was -31% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 44
Price Growth Rating: 42
SMR Rating: 68
Profit Risk Rating: 67
Seasonality Score: 16 (-100 ... +100)
Momentum Indicator for HRTS turns positive, indicating new upward trend